With shares of Corning (NYSE:GLW) trading around $17, is GLW an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework.
T = Trends for a Stock’s MovementCorning produces and sells specialty glasses, ceramics, and related materials worldwide. It operates in five segments: Display Technologies, Telecommunications, Environmental Technologies, Specialty Materials, and Life Sciences. Corning has launched Corning Lotus Glass, an environmentally friendly display glass for organic LED and LCD displays that are used in portable devices such as smartphones, tablets, and notebook computers. Smart phones, tablets, notebook computers, and their related materials are seeing explosive growth in developed and developing countries around the world.
Corning on Tuesday announced its results for the fourth quarter and full year of 2013.�Core earnings per share were 29 cents, an increase of 4 percent over last year�� fourth quarter and better than expected. GAAP earnings per share were 30 cents.�Core sales were $2 billion, a 2 percent decline from the comparable period last year.��013 was a very successful year for Corning,��Wendell P. Weeks, chairman, chief executive officer, and president, said in the earnings report. ��e achieved the company�� primary performance goal of restoring earnings growth. This was accomplished by regaining positive momentum in our LCD business and growing the earnings in our other segments. We also delivered on our commitment to enhance shareholder value by increasing the cash dividend and executing more than $1.5 billion in share repurchases. The company�� performance was recognized by a 41% improvement in the year�� share price, a result with which we are delighted.��/p>
10 Best International Stocks To Watch Right Now: Durata Therapeutics Inc (DRTX)
Durata Therapeutics, Inc., incorporated on November 4, 2009, is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia.
As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin. Dalbavancin achieved its primary efficacy endpoint of non-inferiority in each of these three completed Phase III clinical trials when compared to linezolid, cefazolin or vancomycin, three of the standard-of-care agents for uncomplicated skin and skin structure infections (uSSSI), and complicated skin and skin structure infections (cSSSI). Its two ongoing Phase III clinical trials are designed to compare dalbavancin to vancomycin, with an option to switch to oral linezolid, under the new FDA draft guidance.
The Company competes with Pfizer, Cubist Pharmaceuticals, Inc., Theravance, Inc., Forest Laboratories, Inc., Sanofi-Aventis Ltd., The Medicines Company, Trius Therapeutics, Inc., Cempra, Inc., Rib-X Pharmaceuticals, Inc., Paratek Pharmaceuticals, Inc., Nabriva Therapeutics AG, Tetraphase Pharmaceuticals, Inc. and Furiex Pharmaceuticals, Inc.
Advisors' Opinion:- [By Bob's Stocks]
Durata Therapeutics (DRTX) is developing Dalbavancin, a once a week, intravenous antibiotic product candidate, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. The company is expected to file a NDA (New Drug Application) at any moment and MAA (Marketing Authorization Application) at the end of 2013.
- [By Lisa Levin]
Durata Therapeutics (NASDAQ: DRTX) shares climbed 5.30% to $14.18. The volume of Durata Therapeutics shares traded was 861% higher than normal. The FDA Advisory Committee unanimously recommended the approval of Durata's Dalvance.
Top 10 Life Sciences Companies To Invest In 2014: Meru Networks Inc.(MERU)
Meru Networks, Inc., together with its subsidiaries, provides wireless local area network (LAN) solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It offers a virtualized wireless LAN solution based on its System Director Operating System, which runs on its controllers and access points to enable enterprises to deliver business-critical applications over wireless networks. The company?s System Director Operating System provides centralized coordination and control of various access points on the network; controllers synchronize access points to optimize the user experience and manage traffic on the network; and Wi-Fi certified access points to provide network connectivity for wireless devices. It also offers Meru Networks E(z)RF application suite comprising E(z)RF Network Manager, E(z)RF Service Assurance Manager, E(z)RF Location Manager, E(z)RF OnTheGo, Spectrum Manager, and wired and wireless management solutions, which enable enterprises to configure, monitor, troubleshoot, secure, and operate virtualized wireless LAN solution. In addition, the company provides Identity Manager that simplifies enterprise network access and identity management; Wireless Intrusion Prevention System to recognize and mitigate threats; Compliance Manager to reduce the risk of security breach by protecting customer and employee personal information by extending security to the wireless network; AirFirewall to intercept and block unwanted communications as they transmit over the air, stopping them before they reach the network; and Security Gateway SG1000 to meet the demands of the Federal Information Processing Standard, 140-2 Level 3 security required by federal government agencies and other security-conscious organizations. It serves the education, healthcare, hospitality, manufacturing, retail, technology, finance, government, telecom, transportation, and utility markets. The company was founded in 2002 and is headquartered in Sunnyvale, California.
Advisors' Opinion:- [By Eric Volkman]
Meru Networks (NASDAQ: MERU ) isn't wasting any time in finding a successor to one of its top executives. The company announced Monday it had appointed Brian McDonald to be its new CFO to replace the resigning Brett White. McDonald took up his position today, although White will remain at the firm through July 1 in order "to effect a smooth transition."
Top 10 Life Sciences Companies To Invest In 2014: ABB Ltd(ABB)
ABB Ltd. provides power and automation technologies for utility and industrial customers worldwide. The company?s Power Products division manufactures and sells high- and medium-voltage switchgear and apparatus, circuit breakers, power and distribution transformers, and sensors. ABB?s Power Systems division provides integrated power and automation solutions for power generation plants; alternating current (AC) and direct current (DC) transmission systems; and flexible alternating current systems technologies. It also offers land and submarine cables, as well as accessories and services for medium- to high-voltage AC and DC systems; air- and gas-insulated substations; and network management solutions to help manage power networks. In addition, this division offers support agreements and retrofits to spare parts, service, consulting, and training; and undertakes analyses and design of new transmission and distribution systems. The company?s Discrete Automation and Motion div ision manufactures and sells motors, generators, variable speed drives, programmable logic controllers, rectifiers, excitation systems, robotics, and related services for a range of applications in factory automation, process industries, and utilities. Its Low Voltage Products division provides protection, control, and measurement for electrical installations, enclosures, switchboards, electronics, and electromechanical devices for industrial machines, plants, and related services. It also makes building control systems for home and building automation. The company?s Process Automation division offers integrated process control and instrumentation systems, plant electrification systems, information management systems, and industry-specific application knowledge for industries, such as pulp and paper, minerals and mining, metals, chemicals and pharmaceuticals, oil and gas, turbocharging, power, and marine. ABB Ltd. was founded in 1988 and is headquartered in Zurich, Switzerla nd.
Advisors' Opinion:- [By Cheryl Kaften]
To remain relevant and competitive, current smart grid vendors -- among them ABB (NYSE: ABB ) , General Electric (NYSE: GE ) �, IBM� (NYSE: IBM ) , �and�Siemens� (NYSE: SI ) --�may have to make market adjustments, including partnerships, acquisitions, and advances of their own.
- [By Travis Hoium]
Shares of inverter maker Power-One (NASDAQ: PWER.DL ) have surged 58% higher today after the company received a $1 billion buyout offer from ABB (NYSE: ABB ) . The large electrical component maker offered $6.35 per share for the company and shares have moved slightly past that number, indicating that investors think there's a higher offer coming.
- [By MONEYMORNING]
ABB Ltd (NYSE: ABB) and United Technologies Corporation (NYSE: UTX) are great examples of the kinds of plays I favor for this scenario. They're global concerns providing services and products that are squarely in the path of trillions of dollars in spending.
Top 10 Life Sciences Companies To Invest In 2014: Arch Therapeutics Inc (ARTH)
Arch Therapeutics, Inc. (Arch), formerly Almah, Inc., incorporated on September 16, 2009, operates as a life science company developing polymers containing peptides intended to form gel-like barriers over wounds to stop or control bleeding. Arch is a medical device company offering an approach to the rapid cessation of bleeding (hemostasis) and control of fluid leakage (sealant) during surgery and trauma care. Arch�� products are in preclinical development. The first product, AC5, is designed for hemostasis in minimally invasive (laparoscopic) and open surgical procedures.
AC5
AC5 is a synthetic peptide consisting of naturally occurring amino acids. When squirted or sprayed onto a wound, AC5 intercalates into the nooks and crannies of the connective tissue where it builds itself into a physical, mechanical structure. That structure provides a barrier to leaking substances, including blood and other bodily fluids, regardless of type of surgery or, based on early data, clotting ability.
Advisors' Opinion:- [By Bryan Murphy]
When traders think of post-surgical wound management stocks, they may first think of names like Cytomedix, Inc. (OTCBB:CMXI) or Alliqua Inc. (OTCMKTS:ALQA). And well they should. Both companies have something of a history in the arena. ALQA is the purveyor of SilverSeal and Hydress antibiotic bandages, while CMXI is the developer of the AutoloGel system, which induces an affected patient's on body to do what it's supposed to do if there's a wound that won't heal. Cytomedix also makes the Angel platelet-rich plasma (PRP) delivery system. There's a relatively new name to add to the list of game-changing stocks in wound-management industry, however.... Arch Therapeutics Inc. (OTCBB:ARTH). The company is developing - well, has developed - a product called AC5 that nips post-surgical bleeding in the bud, largely negating the need for other post-surgical bleeding-control measures.
- [By James E. Brumley]
To give credit where it's due, Cytomedix, Inc. (OTCBB:CMXI) and Baxter International Inc. (NYSE:BAX) have both helped shape the landscape of the hemostasis (bleeding control) market with their products, AutoloGel and TISSELL, respectively. Arch Therapeutics Inc. (OTCBB:ARTH) has proverbially taken their concepts "up a notch", however, and its direct solution to a problem that CMXI and BAX can't quite solve may make ARTH the hottest trading candidate in the hemostasis space.
- [By John Udovich]
Laparoscopic surgery or minimally invasive surgery (MIS) is a type of surgical technique where�operations in the abdomen are performed through small incisions while small cap stocks ArthroCare Corporation (NASDAQ: ARTC), EDAP TMS S.A. (NASDAQ: EDAP), SafeStitch Medical Inc (OTCBB: SFES) and Arch Therapeutics Inc (OTCBB: ARTH) are all in some way focused on aiding minimally invasive procedures. According to a 2012 report produced by MedMarket Diligence, LLC, approximately 114 million surgical and procedure-based wounds occur annually worldwide,�including�36 million in the US, and perhaps�up to a quarter of these procedures can be described as laparoscopic in nature.�Moreover,�use of the technique is bound to increase�as�it reduces�pain and hemorrhaging plus leads to a�shorter recovery time.
Top 10 Life Sciences Companies To Invest In 2014: Luxottica Group SpA (LUX)
Luxottica Group S.p.A. (Luxottica), incorporated in 1961, is an Italy-based company engaged in the design, manufacture and distribution of prescription frames and sunglasses in the mid-and premium-price categories. It operates in two segments: manufacturing and wholesale distribution and retail distribution. Through its manufacturing and wholesale distribution segment, it is engaged in the design, manufacture, wholesale distribution and marketing of house and designer lines of mid-to premium-priced prescription frames and sunglasses. The Company operates its retail segment principally through its retail brands, which include, among others, LensCrafters, Pearle Vision, Sears Optical, Target Optical and its Licensed Brands (Sears Optical and Target Optical), as well as through the retail brands of its business, Oakley, which include, among others, Oakley O Stores and Vaults, David Clulow e nel segmento Licensed Brand. Among its subsidiaries there are: Air Sun, Bazooka Inc, David Clulow Brighton Ltd and Ecotop Pty Ltd.
In May 2010, the Company acquired a 35.16% interest held by minority stockholders in Luxottica Gozluk Endustri ve Ticaret Anonim Sirketi, (Luxottica Turkey). On July 30, 2010, Luxottica acquired a 34% interest held by minority stockholders in Sunglass Hut (UK) Limited. On November 26, 2010, it acquired the Optifashion Australia Pty Limited group from HAL Optical Investments B.V. The acquisition included 47 corporate stores (40 optical and seven sun) and nine franchises, trading under brands including Just Spectacles. During the year ended December 31, 2010, the Company completed the acquisition of the David Clulow chain, bringing its ownership in the subsidiary to 100%. Luxottica�� house brands include Ray-Ban, Oakley, Arnette, Persol, REVO, Vogue, Oliver Peoples, K&L, Luxottica, Mosley Tribes, Sferoflex and Eye Safety Systems (ESS). Its licensed designer brands include Anne Klein, Brooks Brothers, Bvlgari, Burberry, Chanel, Dolce & Gabbana, D&G, Donna Karan, DKNY, Fox, Miu ! Miu, Paul Smith, Polo Ralph Lauren, Prada, Salvatore Ferragamo, Stella McCartney, Tiffany & Co, Tory Burch and Versace. Polo Ralph Lauren includes Chaps, Polo, Ralph and Ralph Lauren Purple Label. Product design, development and manufacturing takes place in six production facilities in Italy, two wholly owned factories in China and two sports sunglasses production facilities in the United States. Luxottica also has a small plant in India serving the local market.
During 2010, the Company produced approximately 56.6 million units. In North America, the Company operates the points of sale for its Licensed Brands, with over 1,140 stores under the Sears Optical and Target Optical brands. During 2010, it distributed approximately 20.4 million prescription frames and approximately 38.4 million sunglasses, in approximately 5,900 different styles. During 2010, it announced the signing of a license agreement with Coach, Inc. (Coach) for the design, manufacturing and global distribution of sun and prescription eyewear under the Coach, Coach Poppy and Reed Krakoff brands. Essilor S.A. (Essilor) is the supplier of the Company�� retail operations.
Luxottica�� distribution system is globally integrated and supplied by a centralized manufacturing programming platform. The network linking the logistics and sales centers to the production facilities in Italy and China also provides daily monitoring of global sales performance and inventory levels so that manufacturing resources can be programmed and warehouse stocks re-allocated to meet local market demand. This integrated system serves both the retail and wholesale businesses with 18 distribution centers worldwide, of which eight are in the Americas, seven are in the Asia-Pacific region and three are in the rest of the world. It has three main distribution centers (hubs) in locations serving its markets: Sedico in Europe, Atlanta in the Americas and Dongguan in the Asia-Pacific region. They operate as centralized facilities, offering custo! mers a au! tomated order management system. During 2010, it managed over 13,500 orders per day, including eyeglasses and spare parts. Sedico ships over 170,000 units daily to customers in Europe, the Middle East and Africa and to its distribution centers in the rest of the world, from which they are then shipped to local customers.
Wholesale Distribution
The Company�� wholesale distribution network, covering 130 countries across five continents, has 18 logistics centers and 42 commercial subsidiaries providing direct operations in key markets. Luxottica also distributes certain brands, including Oakley, to sporting goods stores and specialty sports stores, including bike, surf, snow, skate, golf and motor sports stores.
Retail Distribution
The retail portfolio offers a range of differentiation points for consumers, including the latest in designer and sun frames, lens options, eye care and everyday vision care health benefits. As of March 31, 2011, the Company�� retail business consisted of 5,911 corporate stores and 514 franchised or licensed locations. In its retail sun business, Luxottica operates over 2,480 retail locations in North America, Asia-Pacific, South Africa, Europe and the Middle East, mainly through the Sunglass Hut brand. Luxottica�� retail stores sells not only prescription frames and sunglasses that it manufactures but also a range of prescription frames, lenses and other ophthalmic products manufactured by other companies. During 2010, units manufactured with its brand names or its licensed brands represented approximately 80.2% of the total sales of frames based on units sold by the retail division.
Luxottica�� optical retail operations are anchored by brands, such as LensCrafters and Pearle Vision in North America, and OPSM, Laubman & Pank and Budget Eyewear, which are available in Australia and New Zealand. It also has a retail presence in China, where the Company operates in the eyewear market with LensCrafters. As of ! March 31,! 2011, the Company�� optical retail business consisted of approximately 3,650 retail locations globally. As of March 31, 2011, it operated a retail network of 1,191 LensCrafters stores, of which 989 are in North America and 202 stores are in China and Hong Kong. LensCrafters stores offer a range of selection of prescription frames and sunglasses, mostly made by Luxottica, in addition to a range of lenses and optical products made by other suppliers. LensCrafters' products include lenses, such as FeatherWates (lightweight, thin and impact-resistant lenses), DURALENS (super scratch-resistant lenses), Advanced View Progressive (free-form, digitally surfaced progressive lenses), Invisibles (anti-reflective lenses) and MVP Maximum View Progressives (multi-focal lenses without visible lines).
Pearle Vision is a optical retail chain in North America. As of March 31, 2011, Pearle Vision operated 330 corporate stores and had 350 franchise locations throughout North America. The Company also operates a network of retail locations in North America operating as Sears Optical and Target Optical, its Licensed Brands, which uses the brand names of their respective American department store. As of March 31, 2011, it operated 828 Sears Optical and 323 Target Optical locations throughout North America. OPSM includes three optical chains that it operates in Australia and New Zealand. In July 2010, the brand launched its new flagship store OPSM Eye Hub and in September 2010, the brand launched its new OPSM Loves Eyes marketing campaign. As of March 31, 2011, the Company owned 357 OPSM corporate stores throughout Australia. OPSM also has 43 corporate-owned stores in New Zealand, mainly in large urban areas.
Laubman & Pank focuses on the independent optical shopper looking for eyecare and service. As of March 31, 2011, Luxottica owned 65 Laubman & Pank corporate stores throughout Australia. As of March 31, 2011, the Company owned 92 Budget Eyewear corporate stores throughout Australia and had nine! franchis! e locations. Budget Eyewear also has 14 corporate stores in New Zealand. EyeMed Vision Care is a managed vision care operators in the United States, serving over 28.5 million members in large and medium size companies and government entities and through insurance companies. EyeMed has a network of over 24,000 locations, including opticians, ophthalmologists, optometrists and chains operated by Luxottica. Together with LensCrafters' over 900 in-store labs, Luxottica operates five central lens finishing labs in North America. In addition, it operates Oakley optical lens laboratories in the United States, Ireland and Japan. As of March 31, 2011, Sunglass Hut had 2,385 stores worldwide, of which 2,329 are corporate stores and 56 are franchise locations. As of March 31, 2011, the Company operated approximately 590 Sunglass Hut departments in Macy's.
ILORI is Luxottica's fashion sunwear retail brand, with 24 stores in North America, as of March 31, 2011, including flagship stores in the SoHo neighborhood of New York City and in Beverly Hills, California. As of March 31, 2011, the Company operated 24 Optical Shop of Aspen stores in locations throughout the United States. Luxottica operates six luxury retail stores under the Oliver Peoples brand. The Oliver Peoples brand retail stores only offer Oliver Peoples, Mosley Tribes and Paul Smith branded optical products. Two additional Oliver Peoples retail locations are operated under license in Tokyo and Los Angeles. In Europe, it operates David Clulow, an optical retailer operating in the United Kingdom and Ireland. As of March 31, 2011, David Clulow operated 39 corporate-owned locations (including nine joint ventures), four franchise locations and 36 sun stores/concessions. As of March 31, 2011, Bright Eyes operated 51 corporate store locations and 73 franchise locations. As of March 31, 2011, the Company operated 159 Oakley O Stores and Vaults worldwide, offering a range of Oakley products, including sunglasses, apparel, footwear and accessories. An! other sal! es channel is e-commerce, including the Oakley and the Ray-Ban Websites (www.oakley.com, www.Ray-Ban.com).
The Company competes with De Rigo S.p.A., Marchon Eyewear, Inc., Marcolin S.p.A., Safilo Group S.p.A., Silhouette International Schmied AG, Maui Jim, Inc., Wal-Mart, Eye Care Centers of America, Vision Service Plan (VSP), Davis Vision and Spectera.
Advisors' Opinion:- [By shash63]
While analysts might say that Google Glass is not an imminent driver for Himax, but over the long run, it is one of its most important drivers. Google recently entered into a pact with Luxottica (LUX), the maker of Ray-Ban and Oakley brand of sunglasses. Through this deal, Google will be able to sell its Glass as a fashion accessory to a wide range of consumers around the world with the help of Luxottica�� retail network.
- [By Roberto Pedone]
First up is $25 billion eyewear stock Luxottica Group (LUX). Luxottica has posted some solid performance year-to-date, rallying more than 28% since the calendar flipped over to January. But this stock looks downright toxic right now. Here's why.
Luxottica is currently forming a bearish price setup called a descending triangle. The pattern is formed by a horizontal support level below shares at $51 and downtrending resistance to the topside. As shares bounce between those two technically significant price levels, LUX is getting squeezed closer to a breakdown below that $51 price floor. When that happens, we've got our sell signal in this fashion stock.
Declining volume over the course of the setup in LUX adds some confirmation to the trade, but the downtrend in relative strength is the real problem in this chart. LUX has been underperforming the broad market horrifically in the last quarter, and a move through the $51 level would sap a lot more buying pressure from shares.
If you still own LUX, look for that sell signal as your exit.
Top 10 Life Sciences Companies To Invest In 2014: Interactive Leisure Systems Inc (IALS)
InterActive Leisure Systems Inc, formerly Dukeshire Ventures Inc., incorporated on August 2, 1999, is engaged in the development of Digital Versatile Disc (DVD), format known as Versatile Multilayer Disc (VMD). The Company consists of three operating divisions: Optics, Electronics and Media Division. Optics division is responsible for the development of the VMD disc in its entirety, from mastering, replication, printing to packaging besides the VMD replication lines in collaboration with a consortium partners. Electronics division handles development of high definition optical disc players. Media division is responsible for the development of the high definition format for the optical discs themselves together with authoring tools for the media industry to enable them to display their film content on VMD discs. On May 30, 2007, the Company acquired technology and file format to use with VMD players from Semilla Capital Ltd Hong Kong.
The Company is focussed on producing VMD disc in a number of formats including read only, write once, re-writable (RW) and read only/re-writable combined. The VMD drive is very similar to the standard DVD RW drive with modifications to the firmware to instruct the laser to read multiple layers. The modifications in the software re-calibrate the red laser, enabling it to read data on all data layers. The Company has developed its own VMD authoring software.
Advisors' Opinion:- [By Peter Graham]
What�� the Catch With Bison Petroleum Corp? According to various disclosures, a transaction of $6,500 has or will occur to mention Bison Petroleum Corp in various investment newsletters. Last Wednesday, Bison Petroleum Corp provided a corporate update which also included further details about its Independence Prospect plus the appointment of two seasoned advisors. Back in August, Bison Petroleum Corp had acquired a 100% Working Interest (WI) and 80% Net Revenue Interest (NRI) in the 840-acre Independence Prospect located in the ��rolific�� Bighorn Basin, Wyoming and the company is currently developing an exploration plan for these leases plus they have appointed a Vice-President of Explorations and a Senior Geological Advisor. Back in September, Bison Petroleum Corp also announced the appointment of a new CEO and the launch of its corporate website. A quick look at Bison Petroleum Corp�� financials reveals no revenues; net losses of $340k (most recent reported quarter), $16k, $56k and $30k for the past four quarters; and $30k in cash to cover $36k in current liabilities at the end of last July.
Interactive Leisure Systems Inc (OTCMKTS: IALS) Announces AcquisitionsSmall cap Interactive Leisure Systems is a technology company specializing in the global travel industry that intends to purchase an enterprise software platform for the marketing, sale and management of travel products. On Friday, Interactive Leisure Systems sank 16% to $0.021 for a market cap of $1.44 million plus IALS is up 10,400% over the past year and up 425% over the past five years according to Google Finance.
Top 10 Life Sciences Companies To Invest In 2014: Prosensa Holding NV (RNA)
Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company�� primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington�� disease. The Company�� clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Company�� platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.
DMD is a rare, severe muscle wasting disease that occurs in up to 1 in 3,500 male births. It is commonly diagnosed between the ages of three to five, when boys begin to show signs of impaired motor development. PRO044, the Company�� product candidate, addresses a separate sub-population of DMD patients. The Company developed PRO044 using its exon-skipping technology to generate a product candidate with the same mechanism of action that is used by drisapersen.
Advisors' Opinion:- [By Sean Williams]
What: Shares of Prosensa (NASDAQ: RNA ) , a clinical-stage developer of RNA-modulating therapeutic agents for genetic disorders, jumped as much as 50% after reporting additional clinical findings on drisapersen at the JPMorgan Healthcare Conference.
- [By Monica Gerson]
Prosensa Holding NV (NASDAQ: RNA) soared 25.89% to $8.51 in the pre-market trading after the company reported 48-week data from Phase 2 placebo-controlled study of drisapersen in 51 DMD boys.
No comments:
Post a Comment